{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T15:58:33Z","timestamp":1795276713877,"version":"4.10.3"},"reference-count":41,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Dysregulation of immune-checkpoint receptors has been reported at diagnosis of chronic myeloid leukemia (CML), however, their role in the maintenance of remission after tyrosine kinase inhibitor (TKI) cessation is unclear. We assessed programmed cell death-1 (PD-1), T-cell immunoglobulin, and mucin-domain containing protein-3 (TIM-3), cytotoxic T-lymphocyte\u2013associated protein-4 (CTLA-4), lymphocyte-activation gene-3 (LAG-3), and\u00a0T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) expression on T-cell subsets, regulatory T cells (T-regs), and natural killer (NK) cells at the time of TKI cessation in 44 patients (22 patients sustained treatment-free remission [TFR] and 22 experienced molecular relapse [MolR]). We confirmed our previous finding that absolute numbers of T-regs are increased in patients who experienced MolR compared with those who sustained TFR. The immune-checkpoint receptors PD-1, CTLA-4, LAG-3, and TIGIT on T\u00a0or NK cells were not differentially expressed between the MolR and TFR groups. However, TIM-3 was consistently upregulated on bulk T cells (CD3+) and T-cell subsets including, CD4+ T cells, CD8+ T cells, and T-regs, in patients who relapsed in comparison with those who maintained TFR after discontinuation. Furthermore, gene expression analysis from publicly available data sets showed increased TIM-3 expression on CML stem cells compared with normal hematopoietic stem cells. These findings suggest that among the targetable immune-checkpoint molecules, TIM-3 blockade may potentially improve effector immune response in patients with CML stopping TKI, while concomitantly targeting leukemic stem cells and could be a promising therapeutic strategy for preventing relapse after cessation of TKI in patients with CML.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008854","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T15:41:14Z","timestamp":1673278874000},"page":"2364-2374","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-5774","authenticated-orcid":false,"given":"Yazad D.","family":"Irani","sequence":"first","affiliation":[{"name":"1Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2School of Medicine, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung H.","family":"Kok","sequence":"additional","affiliation":[{"name":"1Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2School of Medicine, The University of Adelaide, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Clarson","sequence":"additional","affiliation":[{"name":"1Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8797","authenticated-orcid":false,"given":"Naranie","family":"Shanmuganathan","sequence":"additional","affiliation":[{"name":"1Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2School of Medicine, The University of Adelaide, Adelaide, SA, Australia"},{"name":"3Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia"},{"name":"4Australasian Leukaemia and Lymphoma Group, Melbourne, VIC, Australia"},{"name":"5Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia"},{"name":"6Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-7981","authenticated-orcid":false,"given":"Susan","family":"Branford","sequence":"additional","affiliation":[{"name":"2School of Medicine, The University of Adelaide, Adelaide, SA, Australia"},{"name":"5Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia"},{"name":"6Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-9927","authenticated-orcid":false,"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"1Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2School of Medicine, The University of Adelaide, Adelaide, SA, Australia"},{"name":"3Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia"},{"name":"4Australasian Leukaemia and Lymphoma Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"additional","affiliation":[{"name":"1Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2School of Medicine, The University of Adelaide, Adelaide, SA, Australia"},{"name":"3Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia"},{"name":"4Australasian Leukaemia and Lymphoma Group, Melbourne, VIC, Australia"},{"name":"5Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia"},{"name":"7Department of Haematology, Flinders University and Medical Centre, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0910-3730","authenticated-orcid":false,"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"1Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2School of Medicine, The University of Adelaide, Adelaide, SA, Australia"},{"name":"3Department of Haematology, Royal Adelaide Hospital, Adelaide, SA, Australia"},{"name":"4Australasian Leukaemia and Lymphoma Group, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9452-1533","authenticated-orcid":false,"given":"Agnes S. M.","family":"Yong","sequence":"additional","affiliation":[{"name":"1Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia"},{"name":"2School of Medicine, The University of Adelaide, Adelaide, SA, Australia"},{"name":"4Australasian Leukaemia and Lymphoma Group, Melbourne, VIC, Australia"},{"name":"8The University of Western Australia Medical School, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"1","key":"2023061218031136600_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2023061218031136600_bib2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2023061218031136600_bib3","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023061218031136600_bib4","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2019-125989","article-title":"Lymphocyte subpopulations and expression of immune checkpoint receptors PD-1 and Tim-3 in patients with chronic myeloid leukemia in a discontinuation trial","volume":"134","author":"Seguro","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2023061218031136600_bib5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"3","key":"2023061218031136600_bib6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"2023061218031136600_bib7","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Br\u00fcck","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"2023061218031136600_bib8","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2023061218031136600_bib9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bjh.18302","article-title":"Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype","volume":"198","author":"Harrington","year":"2022","journal-title":"Br J Haematol"},{"key":"2023061218031136600_bib10","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3389\/fimmu.2019.02493","article-title":"NKT-Like (CD3+CD56+) cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"10","author":"Almeida","year":"2019","journal-title":"Front Immunol"},{"key":"2023061218031136600_bib11","doi-asserted-by":"crossref","first-page":"9531549","DOI":"10.1155\/2020\/9531549","article-title":"Increased expression of TIGIT\/CD57 in peripheral blood\/bone marrow NK cells in patients with chronic myeloid leukemia","volume":"2020","author":"Yao","year":"2020","journal-title":"BioMed Res Int"},{"issue":"7","key":"2023061218031136600_bib12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-05-501072","article-title":"Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile","volume":"122","author":"Cramer-Morales","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2023061218031136600_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.18632\/oncotarget.990","article-title":"Genome-wide comparison of the transcriptomes of highly enriched normal and chronic myeloid leukemia stem and progenitor cell populations","volume":"4","author":"Gerber","year":"2013","journal-title":"Oncotarget"},{"issue":"12","key":"2023061218031136600_bib14","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1002\/cam4.1187","article-title":"Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in\u00a0vitro culture with or without imatinib","volume":"6","author":"Avil\u00e9s-V\u00e1zquez","year":"2017","journal-title":"Cancer Med"},{"issue":"6","key":"2023061218031136600_bib15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat Med"},{"issue":"5","key":"2023061218031136600_bib16","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"2023061218031136600_bib17","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1111\/cas.15042","article-title":"TIM-3 in normal and malignant hematopoiesis: structure, function, and signaling pathways","volume":"112","author":"Kikushige","year":"2021","journal-title":"Cancer Sci"},{"issue":"12","key":"2023061218031136600_bib18","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"2023061218031136600_bib19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1182\/bloodadvances.2018028340","article-title":"Frequent germline mutations of HAVCR2 in sporadic subcutaneous panniculitis-like T-cell lymphoma","volume":"3","author":"Polprasert","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2023061218031136600_bib20","doi-asserted-by":"crossref","first-page":"e000911","DOI":"10.1136\/jitc-2020-000911","article-title":"Tim-3 finds its place in the cancer immunotherapy landscape","volume":"8","author":"Acharya","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"24","key":"2023061218031136600_bib21","doi-asserted-by":"crossref","first-page":"20592","DOI":"10.18632\/oncotarget.4112","article-title":"Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer","volume":"6","author":"Xu","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"2023061218031136600_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.imbio.2016.04.005","article-title":"Tim-3 identifies exhausted follicular helper T cells in breast cancer patients","volume":"221","author":"Zhu","year":"2016","journal-title":"Immunobiology"},{"issue":"16","key":"2023061218031136600_bib23","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/bloodadvances.2022007493","article-title":"Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma","volume":"6","author":"Colombo","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"2023061218031136600_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/1878-0261.12029","article-title":"T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer","volume":"11","author":"Liu","year":"2017","journal-title":"Mol Oncol"},{"issue":"33","key":"2023061218031136600_bib25","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2023061218031136600_bib26","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2023061218031136600_bib27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/imm.12665","article-title":"Functional exhaustion of CD4+ T cells induced by co-stimulatory signals from myeloid leukaemia cells","volume":"149","author":"Ozkazanc","year":"2016","journal-title":"Immunology"},{"issue":"4","key":"2023061218031136600_bib28","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/hep.25777","article-title":"Tim-3\/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma","volume":"56","author":"Li","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"2023061218031136600_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/cei.13561","article-title":"Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1\/PD-L1 axis","volume":"204","author":"Solorzano-Ibarra","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2023061218031136600_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023061218031136600_bib31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"issue":"10","key":"2023061218031136600_bib32","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/eji.201545480","article-title":"TIGIT expression levels on human NK cells correlate with functional heterogeneity among healthy individuals","volume":"45","author":"Wang","year":"2015","journal-title":"Eur J Immunol"},{"issue":"3","key":"2023061218031136600_bib33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4049\/jimmunol.0903275","article-title":"Tim-3\/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells","volume":"185","author":"Dardalhon","year":"2010","journal-title":"J\u00a0Immunol"},{"issue":"suppl\u00a01","key":"2023061218031136600_bib34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000431062","article-title":"Identification of TIM-3 as a leukemic stem cell surface molecule in primary acute myeloid leukemia","volume":"89","author":"Kikushige","year":"2015","journal-title":"Oncology"},{"issue":"1","key":"2023061218031136600_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"issue":"18","key":"2023061218031136600_bib36","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/bloodadvances.2021004453C","article-title":"The promise and perils of immunotherapy","volume":"5","author":"Lesch","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2023061218031136600_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/bloodadvances.2019001124","article-title":"Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemia","volume":"4","author":"\u00c7elik","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2023061218031136600_bib38","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker","volume":"108","author":"Jan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2023061218031136600_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2023061218031136600_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"suppl 1","key":"2023061218031136600_bib41","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood-2019-128178","article-title":"Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)","volume":"134","author":"Borate","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2364\/2056738\/blooda_adv-2022-008854-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/11\/2364\/2056738\/blooda_adv-2022-008854-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T18:03:54Z","timestamp":1686593034000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/11\/2364\/494026\/Association-of-TIM-3-checkpoint-receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,6,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008854","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]}}}